ATX Stock Overview
A clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Amplia Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.088 |
| 52 Week High | AU$0.18 |
| 52 Week Low | AU$0.055 |
| Beta | 0.78 |
| 11 Month Change | -41.33% |
| 3 Month Change | -29.60% |
| 1 Year Change | 10.00% |
| 33 Year Change | -51.11% |
| 5 Year Change | 10.00% |
| Change since IPO | -95.60% |
Recent News & Updates
Recent updates
We Think Amplia Therapeutics (ASX:ATX) Needs To Drive Business Growth Carefully
Jan 13
Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth
Apr 28Amplia Therapeutics Limited (ASX:ATX) Insiders Increased Their Holdings
Feb 28Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth
Jan 06
Shareholder Returns
| ATX | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -10.2% | -0.3% | 0.9% |
| 1Y | 10.0% | 11.0% | 18.4% |
Return vs Industry: ATX underperformed the Australian Biotechs industry which returned 11% over the past year.
Return vs Market: ATX underperformed the Australian Market which returned 18.4% over the past year.
Price Volatility
| ATX volatility | |
|---|---|
| ATX Average Weekly Movement | 17.8% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.3% |
Stable Share Price: ATX's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: ATX's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Chris Burns | www.ampliatx.com |
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer, other solid tumors, other fibrotic disease, and scar reduction which is in clinical trial. It also develops AMP886, which is in preclinical trial for treating solid tumors.
Amplia Therapeutics Limited Fundamentals Summary
| ATX fundamental statistics | |
|---|---|
| Market cap | AU$24.18m |
| Earnings (TTM) | -AU$4.50m |
| Revenue (TTM) | AU$4.45m |
5.4x
P/S Ratio-5.4x
P/E RatioIs ATX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATX income statement (TTM) | |
|---|---|
| Revenue | AU$4.45m |
| Cost of Revenue | AU$441.99k |
| Gross Profit | AU$4.01m |
| Other Expenses | AU$8.51m |
| Earnings | -AU$4.50m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.016 |
| Gross Margin | 90.07% |
| Net Profit Margin | -101.14% |
| Debt/Equity Ratio | 13.1% |
How did ATX perform over the long term?
See historical performance and comparison